NovoCure (NVCR) Projected to Post Earnings on Thursday

NovoCure (NASDAQ:NVCR - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, July 24th. Analysts expect NovoCure to post earnings of ($0.40) per share and revenue of $153.87 million for the quarter.

NovoCure (NASDAQ:NVCR - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.16. The company had revenue of $154.99 million for the quarter, compared to the consensus estimate of $147.57 million. NovoCure had a negative net margin of 26.41% and a negative return on equity of 45.46%. The firm's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.36) earnings per share. On average, analysts expect NovoCure to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NovoCure Stock Performance

NVCR opened at $16.59 on Thursday. The company has a current ratio of 1.47, a quick ratio of 1.41 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -10.99 and a beta of 0.72. The company's 50 day moving average is $17.66 and its 200 day moving average is $20.03. NovoCure has a 12-month low of $14.17 and a 12-month high of $34.13.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Piper Sandler reissued an "overweight" rating and issued a $34.00 price objective on shares of NovoCure in a report on Friday, June 27th. Wedbush decreased their target price on shares of NovoCure from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 16th. LADENBURG THALM/SH SH initiated coverage on shares of NovoCure in a research note on Tuesday, July 8th. They set a "buy" rating and a $30.00 target price on the stock. Wall Street Zen cut shares of NovoCure from a "hold" rating to a "sell" rating in a research note on Friday, April 25th. Finally, JPMorgan Chase & Co. decreased their target price on shares of NovoCure from $29.00 to $28.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $32.43.

Institutional Investors Weigh In On NovoCure

Several institutional investors and hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC bought a new stake in shares of NovoCure during the first quarter valued at approximately $87,000. Goldman Sachs Group Inc. raised its position in shares of NovoCure by 5.5% during the first quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider's stock valued at $17,707,000 after buying an additional 52,180 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of NovoCure by 3.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider's stock valued at $1,336,000 after buying an additional 2,502 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in shares of NovoCure by 56.7% during the first quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider's stock valued at $512,000 after buying an additional 10,394 shares during the last quarter. Institutional investors own 84.61% of the company's stock.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.